Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 9, 2011, Pages 1161-1168

  Perera, Vidya ^a,b   Gross, Annette S ^a,c   Xu, Hongmei ^a,b   McLachlan, Andrew J ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b New Hampshire Dartmouth Psychiatric Research Center   (United States)

^c GLAXOSMITHKLINE   (Australia)

Author keywords

caffeine; CYP1A2; pharmacokinetics; plasma; saliva

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; PARAXANTHINE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SALIVA LEVEL; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHENOTYPE; SALIVA ANALYSIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL ENZYME TESTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; HUMANS; MALE; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; REFERENCE VALUES; SALIVA; THEOPHYLLINE; YOUNG ADULT;

EID: 80051675834     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01326.x     Document Type: Article

References (50)

1. Ozdemir V, et al,. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J Clin Psychopharm 2001; 21: 398-407. (Pubitemid 32673029)
2. Bertilsson L, et al,. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471-473. (Pubitemid 24344037)
3. Wilkinson GR,. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-2221.
4. Eaton DL, et al,. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 1995; 5: 259-274.
5. Butler MA, et al,. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989; 86: 7696-7700. (Pubitemid 19265255)
6. Butler MA, et al,. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-127.
7. Gunes A, Dahl M-L,. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 2008; 9: 625-637. (Pubitemid 351803920)
8. Ghotbi R, et al,. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007; 63: 537-546. (Pubitemid 46684487)
9. Farin FM, Omiecinski CJ,. Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue. J Toxicol Environ Health 1993; 40: 317-335. (Pubitemid 23344357)
10. Farin FM, et al,. Expression of cytochrome P450s and microsomal epoxide hydrolase in primary cultures of human umbilical vein endothelial cells. Toxicol Appl Pharm 1994; 124: 1-9. (Pubitemid 24079028)
11. Uno S, et al,. Basal and inducible CYP1 mRNA quantitation and protein localization throughout the mouse gastrointestinal tract. Free Radic Biol Med 2008; 44: 570-583. (Pubitemid 351172715)
12. Campbell ME, et al,. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 1987; 15: 237-249. (Pubitemid 17056770)
13. Gu L, et al,. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2: 73-77.
14. Gu L,. Caffeine Metabolism as Index of Cytochrome P4501A3 Activity, in Medicine. Toronto: University of Toronto, 1992: 116.
15. Tassaneeyakul W, et al,. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994; 47: 1767-1776. (Pubitemid 24172844)
16. Fuhr U, Rost KL,. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4: 109-116. (Pubitemid 24210928)
17. Miners JO, Birkett DJ,. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol 1996; 27: 245-249. (Pubitemid 26129183)
18. Kotake AN, et al,. The caffeine CO2 breath test: dose-response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther 1982; 32: 261-269. (Pubitemid 13000967)
19. Denaro CP, et al,. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance. Clin Pharmacol Ther 1996; 59: 284-296. (Pubitemid 26122200)
20. Rostami-Hodjegan A, et al,. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996; 6: 121-149. (Pubitemid 26153358)
21. Sinues B, et al,. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity. Ther Drug Monit 2002; 24: 715-721. (Pubitemid 35379524)
22. Kalow W, Tang BK,. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53: 503-514. (Pubitemid 23161197)
23. Tang BK, Kalow W,. Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans. Methods Enzymol 1996; 272: 124-131. (Pubitemid 26299874)
24. Alkaysi HN, et al,. High performance liquid chromatographic analysis of caffeine concentrations in plasma and saliva. J Clin Pharm Ther 1988; 13: 109-115.
25. Carrillo JA, et al,. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 2000; 22: 409-417. (Pubitemid 30622112)
26. Tantcheva-Poor I, et al,. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999; 9: 131-144. (Pubitemid 29358995)
27. Bozikas VP, et al,. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. Eur Neuropsychopharm 2004; 14: 39-44. (Pubitemid 37495029)
28. Aklillu E, et al,. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 2003; 64: 659-669. (Pubitemid 37048569)
29. Djordjevic N, et al,. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol 2008; 64: 381-385. (Pubitemid 351322359)
30. Faber MS, et al,. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005; 97: 125-134. (Pubitemid 41291208)
31. Smith PF, et al,. The Safety Aspects of Dietary Caffeine. Canberra: Australia New Zealand Food Authority, 2000.
32. Fernandes O, et al,. Moderate to heavy caffeine consumption during pregnancy and relationship to spontaneous abortion and abnormal fetal growth: a meta-analysis. Reprod Toxicol 1998; 12: 435-444. (Pubitemid 29110875)
33. Perera V, et al,. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomed Chromatogr 2010; 24: 1136-1144.
34. Flynn PM, et al,. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob Agents Chemother 2007; 51: 3516-3522. (Pubitemid 47519338)
35. Sheiner LB, Beal SL,. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-512.
36. Doude van Troostwijk LJAE, et al,. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio. Fundam Clin Pharmacol 2003; 17: 355-362. (Pubitemid 36774171)
37. Lelo A, et al,. Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br J Clin Pharmacol 1986; 22: 177-182. (Pubitemid 17174115)
38. Tanaka E, et al,. A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. Int J Clin Pharmacol Ther 1992; 30: 336-341.
39. Spigset O, et al,. The paraxanthine: caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics 1999; 9: 409-412. (Pubitemid 29376388)
40. Kukongviriyapan V, et al,. Salivary caffeine metabolic ratio in alcohol-dependent subjects. Eur J Clin Pharmacol 2004; 60: 103-107. (Pubitemid 38626439)
41. Biederbick W, et al,. Caffeine in saliva after peroral intake: early sample collection as a possible source of error. Ther Drug Monit 1997; 19: 521-524. (Pubitemid 28116828)
42. Woolridge H, et al,. CYP1A2 in a smoking and a non-smoking population; correlation of urinary and salivary phenotypic ratios. Drug Metabol Drug Interact 2004; 20: 247-261. (Pubitemid 40083058)
43. Tang BK, et al,. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994; 4: 117-124.
44. Cheng WS, et al,. Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clin Pharmacol Ther 1990; 47: 516-524. (Pubitemid 20151478)
45. Newton R, et al,. Plasma and salivary pharmacokinetics of caffeine in man. Eur J Clin Pharmacol 1981; 21: 45-52. (Pubitemid 12237829)
46. Nordmark A, et al,. Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. Br J Clin Pharmacol 1999; 47: 397-402. (Pubitemid 29161272)
47. el-Yazigi A, et al,. Salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases. J Clin Pharmacol 1999; 39: 366-372. (Pubitemid 29159826)
48. Farinati F, et al,. Serum and salivary caffeine clearance in cirrhosis. Any role in selection for surgery and timing for transplantation? J Hepatol 1993; 18: 135-136. (Pubitemid 23166363)
49. Hildebrandt R, Gundert-Remy U,. Lack of pharmacological active saliva levels of caffeine in breast-fed infants. Pediatr Pharmacol 1983; 3: 237-244. (Pubitemid 14102407)
50. Jost G, et al,. Overnight salivary caffeine clearance: a liver function test suitable for routine use. Hepatology 1987; 7: 338-344. (Pubitemid 17062726)